16252-53-2

Usage

Uses

Used in Pharmaceutical Industry:
(2E)-2-(hydroxymethylidene)-6-methoxy-3,4-dihydronaphthalen-1(2H)-one is used as a potential anti-inflammatory and antioxidant agent for the development of new drugs to treat various diseases. Its promising results in studies indicate its potential in the treatment of inflammatory and oxidative stress-related conditions.
Used in Drug Development:
(2E)-2-(hydroxymethylidene)-6-methoxy-3,4-dihydronaphthalen-1(2H)-one is used as a candidate for the development of new drugs due to its potential biological activities and pharmacological properties. It is being evaluated for its potential application in the treatment of various diseases, making it a valuable compound in the field of drug development.

Upstream product

• 109-94-4 formic acid ethyl ester 
• 1078-19-9 6-methoxy-3,4-dihydro-1(2H)-naphthalenone 

Downstream Products

• 62324-90-7 7-methoxy-4,5-dihydro-naphtho[2,1-d]isoxazole 
• 96034-05-8 2-formyl-6-methoxy-2-(p-methoxyphenyl)-3,4-dihydronaphthalen-1(2H)-one 
• 27752-24-5 6-methoxy-2-methyl-3,4-dihydronaphthalen-1(2H)-one 
• 52927-22-7 6-cyano-2-naphthol 
• 67886-70-8 2-cyano-6-methoxynaphthalene 
• 2472-02-8 (±)-6-methoxy-1,2,3,4-tetrahydronaphthalene-2-carbaldehyde 
• 57595-75-2 7-methoxy-2-phenyl-4,5-dihydro-2H-benzo[g]indazole 
• 1402041-07-9 3-(4-bromobenzyl)-6-methoxy-2-methylnaphthalene-1,4-dione 
• 518360-20-8 2-(7-Methoxy-4,5-dihydrobenzo[g]indazol-1-yl)-1-methylethylamine 
• 74039-98-8 2-cyano-6-methoxy-2-methyl-1-tetralone 
• 117661-44-6 7-methoxy-2-nitro-naphto<1,2-b>furan 
• 119047-56-2 1ζ-acetoxy-6-methoxy-2-(p-methoxyphenyl)-2-methyl-1,2,3,4-tetrahydronaphthalene 
• 52924-01-3 6-methoxy-1-(p-methoxyphenyl)-2-methyl-3,4-dihydronaphthalene 
• 96043-75-3 6-methoxy-2-(p-methoxyphenyl)-2-methyl-1,2,3,4-tetrahydronaphthalen-1ζ-ol 

Relevant academic research and scientific papers

Probing Intramolecular Electron Transfer in Redox Tag Processes

Herein, we show that redox tag-guided intermolecular formal [2 + 2] cycloaddition can be used as a probe to investigate intramolecular single-electron transfer (SET) mechanisms. The efficacy of intramolecular SET can be evaluated in association with concomitant carbon-carbon bond formation and/or cleavage, leading to cycloaddition or cross-metathesis. Experimental and theoretical results suggest that the intramolecular SET is under both thermodynamic and kinetic control and can also occur through bonds, not only through space.

Design, Conformation, and Crystallography of 2-Naphthyl Phenyl Ethers as Potent Anti-HIV Agents

Catechol diethers that incorporate a 7-cyano-2-naphthyl substituent are reported as non-nucleoside inhibitors of HIV-1 reverse transcriptase (NNRTIs). Many of the compounds have 1-10 nM potencies toward wild-type HIV-1. An interesting conformational effect allows two unique conformers for the naphthyl group in complexes with HIV-RT. X-ray crystal structures for 4a and 4f illustrate the alternatives.

A Platform of Regioselective Methodologies to Access Polysubstituted 2-Methyl-1,4-naphthoquinone Derivatives: Scope and Limitations

A platform of synthetic methodologies has been established to access a focused library of polysubstituted 3-benzylmenadione derivatives functionalized on the aromatic ring of the naphthoquinone core. Two main routes were explored: 1) The naphthol route, starting from either an α-tetralone or a propiophenone, and 2) the regioselective Diels-Alder reaction, starting from various dienes and two 2-bromo-5(or 6)-methyl-1,4-benzoquinones. 6-Substituted 2-methylnaphthols were synthesized by using a xanthate-mediated free-radical addition/cyclization sequence for the construction of the 6-substituted menadione subunit. Furthermore, an efficient and simple new pathway that allows the formation of 6- or 7-substituted 3-(substituted-benzyl)menadione regioisomers from a common commercial scaffold has also been developed by the naphthol route, advantageous with regard to step economy. Our synthetic methodologies exemplified by 34 compounds have allowed structure-activity relationships to be deduced for use as the basis for the development of new antimalarial redox-active polysubstituted benzylmenadione derivatives.

Novel conformationally constrained pyrazole derivatives as potential anti-cancer agents

The synthesis of 17 novel conformationally constrained pyrazole derivatives is reported herein, along with the assessment of their anti-proliferative and antiangiogenic activities. The evaluation of their inhibitory effect on cell proliferation against He

TOTAL SYNTHESIS OF REDOX-ACTIVE 1.4-NAPHTHOQUINONES AND THEIR METABOLITES AND THEIR THERAPEUTIC USE AS ANTIMALARIAL AND SCHISTOMICIDAL AGENTS

Naphthoquinones, azanaphthoquinones and benxanthones, their process of synthesis and their use as antimalarial or antischistosomal agents.

Total synthesis of redox-active 1.4-naphthoquinones and their metabolites and their therapeutic use as antimalarial and schistomicidal agents

Naphthoquinones, azanaphthoquinones and benxanthones, their process of synthesis and their use as antimalarial or antischistosomal agents.

Nonclassical SNAPFL analogue as a Cy5 resonance energy transfer partner

(Graph Presented) We have synthesized a new SNAPFL analogue (1) that exhibits a large Stokes shift (78 nm) (abs. 542 nm, em. 620 nm) and a good quantum yield. Because of the large overlap between the emission spectrum of 1 and the absorption spectrum of C

Synthesis of 6-Methoxy-2-methyl-2--3,4-dihydronaphthalen-1(2H)-one: Its Novel Base-Catalysed Rearrangement to a Hydrophenanthrene Keto Acid

Reaction of 2-dimethylaminomethyl-6-methoxy-3,4-dihydronaphthalen-1(2H)-one (7) with 2-methylcyclopentane-1,3-dione gave 64percent of 6-methoxy-2--3,4-dihydronaphthalen-1(2H)-one (6a), which with 1 equiv. of ethylene glycol in refluxing benzene in the presence of 4-toluenesulfonic acid yielded a diastereomeric mixture of the 2',2'-ethylenedioxy derivatives (13a,b); the major diastereomer (13a) was shown to have 1'SR,2RS stereochemistry by X-ray crystallography.With an excess of ethylene glycol and prolonged reflux the triketone (6a) underwent aldol cyclization/acetalization to give 9,9,12,12-bis(ethylenedioxy)-3-methoxy-8-methyl-5,6,8,9,10,11-hexahydro-8,11-methano-7H-cycloheptanaphthalene (19).With pyridinium 4-toluenesulfonate as catalyst, aldol cyclization was avoided, and the triketone (6a) afforded 2--6-methoxy-3,4-dihydronaphthalen-1(2H)-one (15).The triketone (6a) and its monoacetal (13a,b) were susceptible to reverse Michael cleavage in reactions with nucleophiles under either acidic or basic conditions.Methylation of the keto diacetal (15), followed by acid hydrolysis, gave 6-methoxy-2-methyl-2-3,4-dihydronaphthalen-1(2H)-one (6b); 2--6-methoxy-2-methyl-3,4-dihydronaphthalen-1(2H)-one (32), resulting from incomplete hydrolysis, was shown to have 1'RS,2RS stereochemistry by X-ray crystallography.The triketone (6b) underwent a novel base-catalysed rearrangement reaction to give 7-methoxy-2ξ,10a-dimethyl-3-oxo-1,2,3,9,10,10a-hexahydrophenanthrene-4-acetic acid (33) which readily afforded the corresponding enol lactone (35).

FARNESYLATED TETRAHYDRO-NAPHTHALENOLS AS HYPOLIPIDEMIC AGENTS

The invention relates to novel farnesylated tetrahydro-naphthalenols, that inhibit HMGR activity which results in a decrease in serum total cholesterol, a decrease in LDL cholesterol levels, and inhibition of LDL oxidation. The farnesylated tetrahydro-nap